Next Article in Journal
Gene Expression Profile as a Predictor of Seizure Liability
Next Article in Special Issue
The Central Noradrenergic System in Neurodevelopmental Disorders: Merging Experimental and Clinical Evidence
Previous Article in Journal
Exploring Novel Therapeutic Targets in the Common Pathogenic Factors in Migraine and Neuropathic Pain
Previous Article in Special Issue
Type I Diabetes Pathoetiology and Pathophysiology: Roles of the Gut Microbiome, Pancreatic Cellular Interactions, and the ‘Bystander’ Activation of Memory CD8+ T Cells
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 24
Issue 4
10.3390/ijms24044115
Review Report
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Article
Peer-Review Record

Impaired Organokine Regulation in Non-Diabetic Obese Subjects: Halfway to the Cardiometabolic Danger Zone

Int. J. Mol. Sci. 2023, 24(4), 4115; https://doi.org/10.3390/ijms24044115
by Hajnalka Lőrincz 1,†, Balázs Ratku 2,3,4,†, Sára Csiha 1,3, Ildikó Seres 1, Zoltán Szabó 2, György Paragh 1, Mariann Harangi 1,4 and Sándor Somodi 2,4,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Int. J. Mol. Sci. 2023, 24(4), 4115; https://doi.org/10.3390/ijms24044115
Submission received: 19 January 2023 / Revised: 14 February 2023 / Accepted: 16 February 2023 / Published: 18 February 2023
(This article belongs to the Special Issue Central and Peripheral Molecular Mechanisms of Metabolism Regulation 3.0)

Round 1

Reviewer 1 Report

I have read with great interest the paper entitled " Impaired organokine regulation in non-diabetic obese subjects: Halfway to cardiometabolic danger zone”. 

The paper is well written and covers a very important issue of cardiometabolic risk in obesity.

I have only minor remarks:

-          The section 4. Materials and methods should be before section 2. Results.

-          Table 1. HbA1c and Insulin – was the difference between NDO and T2DM not significant?

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Reviewer 2 Report

In the current study, the authors have reported the expressions (levels) of afamin and its association with several different metabolic players studied in non-diabetic (NDO) obese and type2 diabetic obese (T2DM) subjects. 

The current study showed that Afamin and PAI-1 found to be markedly higher, while RBP4 was lower in the NDO and T2DM group compared to controls.

Afamin was negatively correlated with LDL size and RBP4, whereas negatively correlated with anthropometric, glucose/lipid parameters and PAI-1. Thereby, the BMI, glucose, intermediate HDL and small HDL were predictors of afamin.

The authors propose that organokine regulation in NDO subjects could be predictor of obesity-related comorbidities, where afamin may serve as a biomarker for the severity of cardiometabolic disturbances in obesity. 

Overall, the study is interesting, well designed and the results are presented with clarity. The conclusions are supported with experimental evidence. I have no major comments and endorse the publication of this work.

 

 

Notes for the authors:

1.       in the abstract and results or legends it was hard to follow in which sample source these organokine were measured (though mentioned in the methods but abstract and results do not indicate the sample source). please includes the sample type in the abstract and in the results, as well as in the legends. E.g., xxxxx was measured or quantified in the blood samples of….

2.       In figure 1: it would be convenient for readers if authors draw the lines along with p-values, showing the comparison between groups.

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Back to TopTop